Butler, Javed

2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction

Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiac pacing and defibrillation studies

Cited by 362

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic

Bhatt, A. S., Moscone, A., McElrath, E. E., Varshney, A. S., Claggett, B. L., Bhatt, D. L., Januzzi, J. L., Butler, J., Adler, D. S., Solomon, S. D., et al. (2020) · Journal of the American College of Cardiology

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 357

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 352

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study

Givertz, M. M., Anstrom, K. J., Redfield, M. M., Deswal, A., Haddad, H., Butler, J., Tang, W. H. W., Dunlap, M. E., LeWinter, M. M., Mann, D. L., et al. (2015) · Circulation

Gout, Hyperuricemia, Uric AcidHeart Failure Treatment and Management

Cited by 296

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 264

Risk factors for heart failure in the elderly: a prospective community-based study

Chen, Y.-T., Vaccarino, V., Williams, C. S., Butler, J., Berkman, L. F., & Krumholz, H. M. (1999) · The American Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 256

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 245

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 242

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 215

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Butler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., et al. (2022) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 206

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study

Spinowitz, B. S., Fishbane, S., Pergola, P. E., Roger, S. D., Lerma, E. V., Butler, J., von Haehling, S., Adler, S. H., Zhao, J., Singh, B., et al. (2019) · Clinical Journal of the American Society of Nephrology

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 198

Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial

Gheorghiade, M., Fonarow, G. C., van Veldhuisen, D. J., Cleland, J. G. F., Butler, J., Epstein, A. E., Patel, K., Aban, I. B., Aronow, W. S., Anker, S. D., et al. (2013) · European Heart Journal

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 192

Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction

Pandey, A., Shah, S. J., Butler, J., Kellogg, D. L., Lewis, G. D., Forman, D. E., Mentz, R. J., Borlaug, B. A., Simon, M. A., Chirinos, J. A., et al. (2021) · Journal of the American College of Cardiology

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 184

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Utility of patient-reported outcome instruments in heart failure

Kelkar, A. A., Spertus, J., Pang, P., Pierson, R. F., Cody, R. J., Pina, I. L., Hernandez, A., & Butler, J. (2016) · JACC: Heart Failure

Heart Failure Treatment and ManagementHealth Education and Validation

Cited by 179

Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry

Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., Heidenreich, P. A., & Fonarow, G. C. (2016) · American Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 160

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes

Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 146

Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization

Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 139

Patient selection in heart failure with preserved ejection fraction clinical trials

Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 139

Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 131

Empagliflozin and major renal outcomes in heart failure

Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 112

Beta-blocker use and outcomes among hospitalized heart failure patients

Butler, J., Young, J. B., Abraham, W. T., Bourge, R. C., Adams, K. F., Clare, R., & O’Connor, C. (2006) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 106